To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Telomerase gene therapy slows ageing, improves health in mice
17-05-2012: Gene therapy allows older mice to live longer, healthier lives report researchers in a new study published in EMBO Molecular Medicine. Mice that received a single gene-therapy treatment to deliver telomerase to different cells in the body showed drastic improvements in health, fitness and longevity. Telomerase is an enzyme that helps to maintain the physical integrity of the ends of chromosomes.
“Gene therapy is typically thought of as a way to deliver genes into cells to correct genetic defects or diseases. However, if we consider that ageing is, at least in part, the consequence of defective gene function, gene therapy is also a valid strategy to delay ageing or to increase lifespan,” said Maria Blasco, one of the lead authors of the study and Director of the Spanish National Cancer Research Centre. “Our results show that telomerase gene therapy is not only a viable anti-ageing intervention but it also has remarkably beneficial effects on health and fitness without increasing the incidence of cancer.”
Telomeres are the caps of repetitive DNA nucleotide sequences that sit at the ends of chromosomes. They are gradually worn down each time a cell divides. Progressive erosion of telomeres eventually stops cells from dividing and leads to cell death.
The scientists used an adeno-associated virus vector to introduce the telomerase gene into the cells of adult mice. Telomerase helps restore longer telomeres by adding DNA back to the ends of chromosomes. “In addition to living longer, engineered mice had stronger bones, improved metabolic functions, better motor coordination and balance, as well as improved performance in object-recognition tests,” said Bruno Bernardes de Jesus, researcher at the Spanish National Cancer Research Centre and lead author of the study.
The mice that were used in the experiments typically live for approximately 150 weeks. One-year-old mice that were treated by gene therapy lived on average 24% longer; the average lifespan of two-year-old mice increased by 13%. By using older mice, the scientists were able to take advantage of the rejuvenating effects of the telomerase enzyme without the increased risk of cancer reported in earlier studies with younger animals.
In a commentary published in the same issue of EMBO Molecular Medicine, Utz Herbig, Assistant Professor at the New Jersey Medical School-University Hospital Cancer Center, remarked: “This work provides an important first proof-of-principle that telomerase gene therapy is a feasible and potentially safe approach to improve the healthy lifespan of older organisms. One of the next steps will be to investigate if similar results can be obtained for other mammals that live significantly longer than mice.”
Bruno Bernardes de Jesus, Elsa Vera, Kerstin Schneeberger, Agueda M Tejera, Eduard Ayuso, Fatima Bosch, Maria A. Blasco; "Telomerase gene therapy in adult and old mice delays ageing and increases longevity without increasing cancer "; EMBO Molecular Medicine
Contact / Request information
Request further information free of charge:
This is where you can add this news to your personal favourites
- 1Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 2Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 3Vivacta Initiates Development of Point of Care Test for Vitamin D
- 4Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 5A light switch inside the brain
- 6Researchers divide enzyme to conquer genetic puzzle
- 7New study confirms fungal infection of the foot is a risk factor for bacterial tissue infection of the leg
- 8Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 9Merck & Co., Inc. Opens Asia Pacific Regional Headquarters in Singapore
- 10Bayer’s Novel Anticoagulant Xarelto now also Approved in the EU
- Going live – immune cell activation in multiple sclerosis
- DNA damage: The dark side of respiration
- EMBO announces new members for 2013
- Evotec and Harvard University to collaborate on development of new class of antibacterials
- Carl Zeiss Meditec improves its results in first six months of financial year 2012/2013